

Andreas Lind

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6362451/publications.pdf>

Version: 2024-02-01

26
papers

1,154
citations

623574

14
h-index

552653

26
g-index

33
all docs

33
docs citations

33
times ranked

2455
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | The incidence of infectious diseases and viruses other than SARS-CoV-2 amongst hospitalised children in Oslo, Norway during the Covid-19 pandemic 2020â€”2021. <i>Journal of Clinical Virology Plus</i> , 2022, 2, 100060. | 0.4 | 14 |
| 2 | Dispersion of SARSâ€”CoVâ€”2 in air surrounding COVIDâ€”19â€”infected individuals with mild symptoms. <i>Indoor Air</i> , 2022, 32, e13001. | 2.0 | 2 |
| 3 | Detailed stratified GWAS analysis for severe COVID-19 in four European populations. <i>Human Molecular Genetics</i> , 2022, 31, 3945-3966. | 1.4 | 46 |
| 4 | Elevated markers of gut leakage and inflammasome activation in COVIDâ€”19 patients with cardiac involvement. <i>Journal of Internal Medicine</i> , 2021, 289, 523-531. | 2.7 | 76 |
| 5 | Observed reduction in the diagnosis of acute lymphoblastic leukaemia in children during the COVIDâ€”19 pandemic. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2021, 110, 596-597. | 0.7 | 16 |
| 6 | Elevated plasma sTIM-3 levels in patients with severe COVID-19. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 92-98. | 1.5 | 31 |
| 7 | Pre-screening and preventive quarantine likely explains the low SARS-CoV-2 prevalence among Norwegian conscripts. <i>Scandinavian Journal of Primary Health Care</i> , 2021, 39, 31-34. | 0.6 | 2 |
| 8 | Severe acute respiratory syndrome coronavirus 2 prevalence in 1170 asymptomatic Norwegian conscripts. <i>Health Science Reports</i> , 2021, 4, e233. | 0.6 | 1 |
| 9 | The use of eculizumab in <i>Capnocytophaga canimorsus</i> associated thrombotic microangiopathy: a case report. <i>BMC Infectious Diseases</i> , 2021, 21, 137. | 1.3 | 1 |
| 10 | Rapid SARS-CoV-2 variant monitoring using PCR confirmed by whole genome sequencing in a high-volume diagnostic laboratory. <i>Journal of Clinical Virology</i> , 2021, 141, 104906. | 1.6 | 21 |
| 11 | Persisting symptoms three to eight months after non-hospitalized COVID-19, a prospective cohort study. <i>PLoS ONE</i> , 2021, 16, e0256142. | 1.1 | 39 |
| 12 | Outbreak caused by the SARS-CoV-2 Omicron variant in Norway, November to December 2021. <i>Eurosurveillance</i> , 2021, 26, . | 3.9 | 252 |
| 13 | Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 25018-25025. | 3.3 | 279 |
| 14 | Increased interleukin-6 and macrophage chemoattractant protein-1 are associated with respiratory failure in COVID-19. <i>Scientific Reports</i> , 2020, 10, 21697. | 1.6 | 65 |
| 15 | Distinct and early increase in circulating MMP-9 in COVID-19 patients with respiratory failure. <i>Journal of Infection</i> , 2020, 81, e41-e43. | 1.7 | 129 |
| 16 | En mann i 90-Ã¥rene med feber og tÃ¥rrhoste. <i>Tidsskrift for Den Norske LÃ¥egeforening</i> , 2020, 140, . | 0.2 | 3 |
| 17 | Status for vaksineutvikling mot covid-19. <i>Tidsskrift for Den Norske LÃ¥egeforening</i> , 2020, 140, . | 0.2 | 1 |
| 18 | Regulation of Gag- and Env-Specific CD8+ T Cell Responses in ART-NaÃ“ve HIV-Infected Patients: Potential Implications for Individualized Immunotherapy. <i>PLoS ONE</i> , 2016, 11, e0153849. | 1.1 | 2 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | High MIP-1 β Levels in Plasma Predict Long-Term Immunological Nonresponse to Suppressive Antiretroviral Therapy in HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 69, 395-402. | 0.9 | 6 |
| 20 | A Parameter for IL-10 and TGF- β Mediated Regulation of HIV-1 Specific T Cell Activation Provides Novel Information and Relates to Progression Markers. <i>PLoS ONE</i> , 2014, 9, e85604. | 1.1 | 8 |
| 21 | Intranasal Administration of a Therapeutic HIV Vaccine (Vacc-4x) Induces Dose-Dependent Systemic and Mucosal Immune Responses in a Randomized Controlled Trial. <i>PLoS ONE</i> , 2014, 9, e112556. | 1.1 | 22 |
| 22 | Boosters of a therapeutic HIV-1 vaccine induce divergent T cell responses related to regulatory mechanisms. <i>Vaccine</i> , 2013, 31, 4611-4618. | 1.7 | 10 |
| 23 | Circulating levels of HMGB1 are correlated strongly with MD2 in HIV-infection: Possible implication for TLR4-signalling and chronic immune activation. <i>Innate Immunity</i> , 2013, 19, 290-297. | 1.1 | 22 |
| 24 | Intradermal vaccination of HIV-infected patients with short HIV Gag p24-like peptides induces CD4 + and CD8 + T cell responses lasting more than seven years. <i>Scandinavian Journal of Infectious Diseases</i> , 2012, 44, 566-572. | 1.5 | 16 |
| 25 | An Exploratory Trial of Cyclooxygenase Type 2 Inhibitor in HIV-1 Infection: Downregulated Immune Activation and Improved T Cell-Dependent Vaccine Responses. <i>Journal of Virology</i> , 2011, 85, 6557-6566. | 1.5 | 58 |
| 26 | Overestimation of Human Immunodeficiency Virus Type 1 Load Caused by the Presence of Cells in Plasma from Plasma Preparation Tubes. <i>Journal of Clinical Microbiology</i> , 2009, 47, 2170-2174. | 1.8 | 18 |